Nuvation Bio Inc. (NYSE:NUVB) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Nuvation Bio Inc. (NYSE:NUVB) have received a consensus recommendation of “Moderate Buy” from the ten research firms that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and eight have assigned a buy recommendation to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $11.6250.

NUVB has been the subject of a number of research reports. HC Wainwright dropped their price target on Nuvation Bio from $18.00 to $17.00 and set a “buy” rating for the company in a research note on Monday, January 12th. UBS Group dropped their price target on Nuvation Bio from $10.00 to $7.00 and set a “neutral” rating for the company in a research note on Tuesday, March 3rd. Truist Financial set a $13.00 price target on Nuvation Bio in a research note on Tuesday, January 27th. Wedbush reiterated an “outperform” rating and issued a $11.00 price target on shares of Nuvation Bio in a research note on Thursday, April 16th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nuvation Bio in a research report on Tuesday, April 21st.

Insider Buying and Selling at Nuvation Bio

In related news, insider Kerry Wentworth sold 200,000 shares of the firm’s stock in a transaction on Monday, April 6th. The stock was sold at an average price of $4.52, for a total transaction of $904,000.00. Following the completion of the transaction, the insider directly owned 53,000 shares of the company’s stock, valued at $239,560. This trade represents a 79.05% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Dongfang Liu sold 50,000 shares of the firm’s stock in a transaction on Friday, April 17th. The stock was sold at an average price of $5.02, for a total value of $251,000.00. Following the transaction, the insider directly owned 18,000 shares of the company’s stock, valued at approximately $90,360. This represents a 73.53% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 286,750 shares of company stock valued at $1,339,118. 30.11% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Parallel Advisors LLC raised its position in Nuvation Bio by 51.9% during the 3rd quarter. Parallel Advisors LLC now owns 7,597 shares of the company’s stock worth $28,000 after purchasing an additional 2,597 shares during the last quarter. Kestra Advisory Services LLC bought a new position in Nuvation Bio during the 4th quarter worth $71,000. Patriot Financial Group Insurance Agency LLC bought a new position in Nuvation Bio during the 1st quarter worth $43,000. Swiss Life Asset Management Ltd acquired a new stake in Nuvation Bio during the 3rd quarter worth about $39,000. Finally, Northwest Quadrant Wealth Management LLC acquired a new stake in Nuvation Bio during the 3rd quarter worth about $40,000. 61.67% of the stock is owned by institutional investors.

Nuvation Bio Stock Up 0.6%

Shares of NUVB opened at $4.48 on Friday. Nuvation Bio has a 52 week low of $1.57 and a 52 week high of $9.75. The stock has a market capitalization of $1.56 billion, a price-to-earnings ratio of -7.46 and a beta of 1.51. The company has a debt-to-equity ratio of 0.15, a quick ratio of 6.81 and a current ratio of 6.95. The stock has a fifty day moving average of $4.72 and a 200-day moving average of $5.90.

Nuvation Bio (NYSE:NUVB) last announced its quarterly earnings results on Monday, March 2nd. The company reported ($0.11) EPS for the quarter, meeting analysts’ consensus estimates of ($0.11). Nuvation Bio had a negative return on equity of 57.48% and a negative net margin of 325.31%.The company had revenue of $41.87 million during the quarter, compared to analysts’ expectations of $36.82 million. As a group, sell-side analysts anticipate that Nuvation Bio will post -0.47 earnings per share for the current fiscal year.

About Nuvation Bio

Nuvation Bio is a clinical-stage biotechnology company dedicated to discovering and developing small-molecule therapies for patients with cancer. The company employs an integrated research and development platform that spans target identification, preclinical evaluation, process chemistry, and early-stage clinical trials. By centralizing these capabilities, Nuvation Bio aims to accelerate the translation of promising drug candidates from laboratory research to first-in-human studies.

The company’s pipeline comprises multiple oncology programs, with small-molecule kinase inhibitors and targeted agents in Phase 1 development for both hematologic malignancies and solid tumors.